Comparison of Etest and agar dilution for determining minimum inhibitory concentration of vancomycin to healthcare-associated methicillin-resistant Staphylococcus aureus

Jyoti Kumari, M. Shalini Shenoy, M. Chakrapani, K. Vidyalakshmi, K. Gopalkrishna Bhat

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: To compare agar dilution method and Etest in the determination of minimum inhibitory concentration (MIC) of vancomycin to healthcare-associated methicillin-resistant Staphylococcus aureus (HA-MRSA). Methods: A total of 98 non-duplicate strains of HA-MRSA isolated from different clinical specimens were tested for their antibiotic susceptibility pattern by Kirby-Bauer disk diffusion method and vancomycin MIC by agar dilution method and Etest (BioMerieux, France). Results: Out of 98 strains of HA-MRSA, 94 (95.9%) were vancomycin susceptible (MIC ≤2 μg/ml and 4 (4.1%) were vancomycin intermediate (MIC 4 μg/ml) by agar dilution method. By Etest, 53 (54.1%) were vancomycin susceptible, 4 (4.1%) were vancomycin intermediate, and the remaining 41 isolates had vancomycin MIC between 2 μg/ml and 4 μg/ml. Conclusion: Etest allows the detection of HA-MRSA strains with intermediate MIC values in addition to traditional dilutions. These properties will help in detection of MIC creep and also decision-making in using vancomycin for the treatment of serious infections caused by HA-MRSA.

Original languageEnglish
Pages (from-to)189-191
Number of pages3
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume9
Issue number4
Publication statusPublished - 01-07-2016

Fingerprint

Disk Diffusion Antimicrobial Tests
Microbial Sensitivity Tests
Vancomycin
Methicillin-Resistant Staphylococcus aureus
Agar
Delivery of Health Care
Cross Infection
France
Decision Making
Anti-Bacterial Agents

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{1eb84a30b4884cb1b6e3627e378e2136,
title = "Comparison of Etest and agar dilution for determining minimum inhibitory concentration of vancomycin to healthcare-associated methicillin-resistant Staphylococcus aureus",
abstract = "Objectives: To compare agar dilution method and Etest in the determination of minimum inhibitory concentration (MIC) of vancomycin to healthcare-associated methicillin-resistant Staphylococcus aureus (HA-MRSA). Methods: A total of 98 non-duplicate strains of HA-MRSA isolated from different clinical specimens were tested for their antibiotic susceptibility pattern by Kirby-Bauer disk diffusion method and vancomycin MIC by agar dilution method and Etest (BioMerieux, France). Results: Out of 98 strains of HA-MRSA, 94 (95.9{\%}) were vancomycin susceptible (MIC ≤2 μg/ml and 4 (4.1{\%}) were vancomycin intermediate (MIC 4 μg/ml) by agar dilution method. By Etest, 53 (54.1{\%}) were vancomycin susceptible, 4 (4.1{\%}) were vancomycin intermediate, and the remaining 41 isolates had vancomycin MIC between 2 μg/ml and 4 μg/ml. Conclusion: Etest allows the detection of HA-MRSA strains with intermediate MIC values in addition to traditional dilutions. These properties will help in detection of MIC creep and also decision-making in using vancomycin for the treatment of serious infections caused by HA-MRSA.",
author = "Jyoti Kumari and {Shalini Shenoy}, M. and M. Chakrapani and K. Vidyalakshmi and {Gopalkrishna Bhat}, K.",
year = "2016",
month = "7",
day = "1",
language = "English",
volume = "9",
pages = "189--191",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "4",

}

TY - JOUR

T1 - Comparison of Etest and agar dilution for determining minimum inhibitory concentration of vancomycin to healthcare-associated methicillin-resistant Staphylococcus aureus

AU - Kumari, Jyoti

AU - Shalini Shenoy, M.

AU - Chakrapani, M.

AU - Vidyalakshmi, K.

AU - Gopalkrishna Bhat, K.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Objectives: To compare agar dilution method and Etest in the determination of minimum inhibitory concentration (MIC) of vancomycin to healthcare-associated methicillin-resistant Staphylococcus aureus (HA-MRSA). Methods: A total of 98 non-duplicate strains of HA-MRSA isolated from different clinical specimens were tested for their antibiotic susceptibility pattern by Kirby-Bauer disk diffusion method and vancomycin MIC by agar dilution method and Etest (BioMerieux, France). Results: Out of 98 strains of HA-MRSA, 94 (95.9%) were vancomycin susceptible (MIC ≤2 μg/ml and 4 (4.1%) were vancomycin intermediate (MIC 4 μg/ml) by agar dilution method. By Etest, 53 (54.1%) were vancomycin susceptible, 4 (4.1%) were vancomycin intermediate, and the remaining 41 isolates had vancomycin MIC between 2 μg/ml and 4 μg/ml. Conclusion: Etest allows the detection of HA-MRSA strains with intermediate MIC values in addition to traditional dilutions. These properties will help in detection of MIC creep and also decision-making in using vancomycin for the treatment of serious infections caused by HA-MRSA.

AB - Objectives: To compare agar dilution method and Etest in the determination of minimum inhibitory concentration (MIC) of vancomycin to healthcare-associated methicillin-resistant Staphylococcus aureus (HA-MRSA). Methods: A total of 98 non-duplicate strains of HA-MRSA isolated from different clinical specimens were tested for their antibiotic susceptibility pattern by Kirby-Bauer disk diffusion method and vancomycin MIC by agar dilution method and Etest (BioMerieux, France). Results: Out of 98 strains of HA-MRSA, 94 (95.9%) were vancomycin susceptible (MIC ≤2 μg/ml and 4 (4.1%) were vancomycin intermediate (MIC 4 μg/ml) by agar dilution method. By Etest, 53 (54.1%) were vancomycin susceptible, 4 (4.1%) were vancomycin intermediate, and the remaining 41 isolates had vancomycin MIC between 2 μg/ml and 4 μg/ml. Conclusion: Etest allows the detection of HA-MRSA strains with intermediate MIC values in addition to traditional dilutions. These properties will help in detection of MIC creep and also decision-making in using vancomycin for the treatment of serious infections caused by HA-MRSA.

UR - http://www.scopus.com/inward/record.url?scp=84978152347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978152347&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 189

EP - 191

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 4

ER -